Anna Petryk1, Roopa Kanakatti Shankar, Neelam Giri, Anthony N Hollenberg, Meilan M Rutter, Brandon Nathan, Maya Lodish, Blanche P Alter, Constantine A Stratakis, Susan R Rose. 1. Division of Pediatric Endocrinology (A.P., B.N.), University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota 55454; Department of Pediatrics (R.K.S.), Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia 23229; Clinical Genetics Branch (N.G., B.P.A.), Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20850; Division of Endocrinology, Diabetes and Metabolism (A.N.H.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; Division of Endocrinology (M.M.R., S.R.R.), Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229; Pediatric Endocrinology Inter-Institute Training Program (M.L.), National Institutes of Health, Bethesda, Maryland 20892; and Section on Endocrinology and Genetics (M.L., C.A.S.), Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland 20892.
Abstract
CONTEXT: Endocrine problems are common in patients with Fanconi anemia (FA). About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility. The goal of this report is to provide an overview of endocrine abnormalities and guidelines for routine screening and treatment to allow early diagnosis and timely intervention. EVIDENCE ACQUISITION: This work is based on a comprehensive literature review, including relevant articles published between 1971 and 2014, and proceedings of a Consensus Conference held by the Fanconi Anemia Research Fund in 2013. EVIDENCE SYNTHESIS: The panel of experts collected published evidence and discussed its relevance to reflect current information about the endocrine care of children and adults with FA before the Consensus Conference and through subsequent deliberations that led to the consensus. CONCLUSIONS: Individuals with FA should be routinely screened for endocrine abnormalities, including evaluation of growth; glucose, insulin, and lipid metabolism; thyroid function; puberty; gonadal function; and bone mineral metabolism. Inclusion of an endocrinologist as part of the multidisciplinary patient care team is key to providing comprehensive care for patients with FA.
CONTEXT: Endocrine problems are common in patients with Fanconi anemia (FA). About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility. The goal of this report is to provide an overview of endocrine abnormalities and guidelines for routine screening and treatment to allow early diagnosis and timely intervention. EVIDENCE ACQUISITION: This work is based on a comprehensive literature review, including relevant articles published between 1971 and 2014, and proceedings of a Consensus Conference held by the Fanconi Anemia Research Fund in 2013. EVIDENCE SYNTHESIS: The panel of experts collected published evidence and discussed its relevance to reflect current information about the endocrine care of children and adults with FA before the Consensus Conference and through subsequent deliberations that led to the consensus. CONCLUSIONS: Individuals with FA should be routinely screened for endocrine abnormalities, including evaluation of growth; glucose, insulin, and lipid metabolism; thyroid function; puberty; gonadal function; and bone mineral metabolism. Inclusion of an endocrinologist as part of the multidisciplinary patient care team is key to providing comprehensive care for patients with FA.
Authors: Michael A Pulsipher; Roderick Skinner; George B McDonald; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Clarisa Gracia; Anna Petryk; Smita Bhatia; Nancy Bunin; Michael L Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; K Scott Baker Journal: Biol Blood Marrow Transplant Date: 2012-01-14 Impact factor: 5.742
Authors: Briana C Patterson; Yan Chen; Charles A Sklar; Joseph Neglia; Yutaka Yasui; Ann Mertens; Gregory T Armstrong; Anna Meadows; Marilyn Stovall; Leslie L Robison; Lillian R Meacham Journal: J Clin Endocrinol Metab Date: 2014-02-25 Impact factor: 5.958
Authors: Susan R Rose; Kasiani C Myers; Meilan M Rutter; Robin Mueller; Jane C Khoury; Parinda A Mehta; Richard E Harris; Stella M Davies Journal: Pediatr Blood Cancer Date: 2012-01-31 Impact factor: 3.167
Authors: Jie Li; Jared Sipple; Suzette Maynard; Parinda A Mehta; Susan R Rose; Stella M Davies; Qishen Pang Journal: Antioxid Redox Signal Date: 2012-06-25 Impact factor: 8.401
Authors: Gregory P Forlenza; Lynda E Polgreen; Bradley S Miller; Margaret L MacMillan; John E Wagner; Anna Petryk Journal: Pediatr Blood Cancer Date: 2013-12-24 Impact factor: 3.167
Authors: Allison L Bartlett; Lindsey Romick-Rosendale; Adam Nelson; Sheyar Abdullah; Nathan Luebbering; Jamen Bartlett; Marion Brusadelli; Joseph S Palumbo; Kelly Lake; Bridget Litts; Alexandra Duell; Annette Urbanski; Adam Lane; Kasiani C Myers; Susanne I Wells; Stella M Davies Journal: Blood Adv Date: 2021-01-12
Authors: Elizabeth S Moore; Erin K Daugherity; David I Karambizi; Bethany P Cummings; Erica Behling-Kelly; Deanna M W Schaefer; Teresa L Southard; Joseph W McFadden; Robert S Weiss Journal: J Biol Chem Date: 2019-08-21 Impact factor: 5.157
Authors: L C de Kloet; J E Bense; M Y E C van der Stoep; M Louwerens; E G J von Asmuth; A C Lankester; A P J de Pagter; S E Hannema Journal: Bone Marrow Transplant Date: 2022-07-15 Impact factor: 5.174
Authors: Jessie L Barnum; Anna Petryk; Lei Zhang; Todd E DeFor; K Scott Baker; Julia Steinberger; Brandon Nathan; John E Wagner; Margaret L MacMillan Journal: Biol Blood Marrow Transplant Date: 2016-05-12 Impact factor: 5.742